Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 12;4(12):877-887.
doi: 10.1002/acn3.494. eCollection 2017 Dec.

Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders

Darcy A Krueger  1 , Anjali Sadhwani  2 , Anna W Byars  1 , Petrus J de Vries  3 , David N Franz  1 , Vicky H Whittemore  4 , Rajna Filip-Dhima  5 , Donna Murray  6   7 , Kush Kapur  5 , Mustafa Sahin  5
Affiliations

Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders

Darcy A Krueger et al. Ann Clin Transl Neurol. .

Abstract

Objective: To evaluate if short-term treatment with everolimus was safe and could improve neurocognition and behavior in children with TSC.

Methods: This was a prospective, double-blind randomized, placebo-controlled two-center phase II study. Participants diagnosed with TSC and age 6-21 years were treated with 4.5 mg/m2 per day of oral everolimus (n = 32) or matching placebo (n = 15) taken once daily for 6 months. For efficacy, a comprehensive neurocognitive and behavioral evaluation battery was performed at baseline, 3 months, and 6 months. For safety, adverse events recorded continuously via patient diary were categorized and graded per NCI Common Toxicity Criteria for Adverse Events, version 3.0 (CTCAE 3.0). Analyses were performed on the intention-to-treat population (n = 47).

Results: Nearly all assessment measures failed to demonstrate significant differences between the two groups at the end of 6 months. Only one measure each of executive function (Cambridge Neuropsychological Test Automated Battery Stockings of Cambridge) favoring placebo (P = 0.025) and social cognition (Social Responsiveness Scale Social Cognition Subscale) favoring everolimus (P = 0.011) was observed. A total of 473 adverse events (AE) were reported. The average number of total AE per subject was similar for both placebo and everolimus. Most were mild or moderate in severity and serious AE were rare.

Interpretation: While safe, oral everolimus administered once daily for 6 months did not significantly improve neurocognitive functioning or behavior in children with TSC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient flow diagram.
Figure 2
Figure 2
Individual Treatment Response for CANTAB Stockings of Cambridge (A) and SRS Social Cognition (B). Waterfall plots show percentage change in average number of errors on the SOC (A) and SRS T‐score (B) after 6 months treatment with everolimus (blue) or placebo (red), compared to baseline, for each participant completing both assessments.
See this image and copyright information in PMC

References

    1. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274–293. - PMC - PubMed
    1. Lipton JO, Sahin M. The neurology of mTOR. Neuron 2014;84:275–291. - PMC - PubMed
    1. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. The Lancet 2008;372:657–668. - PubMed
    1. de Vries PJ, Whittemore VH, Leclezio L, et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND checklist. Pediatr Neurol 2015;52:25–35. - PMC - PubMed
    1. Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol 2015;14:733–745. - PubMed

LinkOut - more resources